Cost effectiveness of trastuzumab in adjuvant treatment of early breast cancer: A model based analysis

被引：0
|
作者：
Dedes, Konstantin J.
Szucs, Thomas D.
Imesch, Patrick
Fehr, Mathias K.
Fink, Daniel
机构：
[1] Univ Zurich Hosp, Div Gynecol, CH-8091 Zurich, Switzerland
[2] Univ Zurich, Inst Social & Prevent Med, CH-8006 Zurich, Switzerland
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+breast cancer.
    Garrison, L. P., Jr.
    Perez, E. A.
    Dueck, A.
    Lalla, D.
    Paton, V.
    Lubeck, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 306S - 306S
  • [22] Adjuvant Trastuzumab Treatment without Adjuvant Chemotherapy in Early Breast Cancer
    Dall, P.
    Koch, T.
    Lenzen, G.
    Kuhn, T.
    Hielscher, C.
    Reichert, D.
    Maasberg, M.
    Ehscheidt, P.
    Eustermann, H.
    Fischer, G.
    CANCER RESEARCH, 2011, 71
  • [23] Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium
    Neyt, Mattias
    Huybrechts, Michel
    Hulstaert, Frank
    Vrijens, France
    Ramaekers, Dirk
    HEALTH POLICY, 2008, 87 (02) : 146 - 159
  • [24] Adjuvant trastuzumab in early breast cancer
    Mariani, G.
    Gianni, L.
    ANNALS OF ONCOLOGY, 2006, 17 : X54 - X58
  • [25] COST-EFFECTIVENESS OF TRASTUZUMAB In the Treatment of Early Stages Breast Cancer Patients, in Portugal
    Macedo, Ana
    Monteiro, Isabel
    Andrade, Sofia
    Cirrincione, A.
    Ray, J.
    ACTA MEDICA PORTUGUESA, 2010, 23 (03): : 475 - 482
  • [26] A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
    Kurian, Allison W.
    Newton Thompson, Rebecca
    Gaw, Allison F.
    Arai, Sally
    Ortiz, Rafael
    Garber, Alan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) : 634 - 641
  • [27] Cost-effectiveness analysis of adjuvant therapy with trastuzumab for HER2-positive early breast cancer in polish setting
    Orlewska, E.
    Pienkowski, T.
    Drosik, K.
    Gyldmark, M.
    Aultman, R.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2007, 10 (03) : A125 - A125
  • [28] Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
    Amir Ansaripour
    Carin A. Uyl-de Groot
    W. Ken Redekop
    PharmacoEconomics, 2018, 36 : 91 - 103
  • [29] Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
    Ansaripour, Amir
    Uyl-de Groot, Carin A.
    Redekop, W. Ken
    PHARMACOECONOMICS, 2018, 36 (01) : 91 - 103
  • [30] Trastuzumab in the adjuvant treatment of breast cancer
    Svetlovska, D.
    Mardiak, J.
    Kristova, V
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2007, 108 (02): : 100 - 103
12345